Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
445results about "Immunoglobulins against blood coagulation factors" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Production of Bispecific Antibodies
InactiveUS20090182127A1Reduce interactionImmunoglobulins against blood coagulation factorsHybrid immunoglobulinsConstant domainHeavy chain
Bispecific antibodies comprising (a) a first light-heavy chain pair having specificity for a first target and a sufficient number of substitutions in its heavy chain constant domain with respect to a corresponding wild-type antibody of the same isotype to significantly reduce the formation of first heavy chain-first heavy chain dimers and (b) a second light-heavy chain pair comprising a heavy chain having a sequence that is complementary to the sequence of the first pair heavy chain sequence with respect to the formation of intramolecular ionic interactions, wherein the first pair or second pair comprises a substitution in the light chain and complementary substitution in the heavy chain that reduces the ability of the light chain to interact with the heavy chain of the other light chain-heavy chain pair are provided. Methods of producing such antibodies in one or more cells also are provided.
Owner:NOVO NORDISK AS
Serum albumin binding peptides for tumor targeting
InactiveUS20050287153A1Altered pharmacodynamicsFacilitated DiffusionImmunoglobulins against blood coagulation factorsImmunoglobulins against cell receptors/antigens/surface-determinantsAbnormal tissue growthPeptide ligand
Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.
Owner:GENENTECH INC
Anti-C5 monoclonal antibodies
InactiveUS6534058B2High affinityMaximizing characteristicImmunoglobulins against blood coagulation factorsAnimal cellsAcute vascular rejectionOligonucleotide
Owner:GENENTECH INC
Methods for generating multimeric molecules
InactiveUS20050136051A1Immunoglobulins against blood coagulation factorsHybrid immunoglobulinsBispecific antibodyIn vivo
Owner:SCALLON BERNARD
Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
InactiveUS20140072581A1Promote formationImmunoglobulins against blood coagulation factorsSenses disorderHeavy chainSingle-Chain Fv
Disclosed herein is an isolated immunoglobulin construct comprising a first monomeric polypeptide comprising a first single chain Fv polypeptide connected to a first constant domain polypeptide; and a second monomeric polypeptide comprising a second single chain Fv polypeptide, connected to a second constant domain polypeptide; each said constant domain polypeptide comprising at least one each of a CL domain, a CH1 domain, a CH2 domain and a CH3 domain or fragments, variants or derivatives thereof; and wherein said first and second constant domain polypeptide form a Fc region.
Owner:ZYMEWORKS INC
Bispecific antibody substituting for functional proteins
ActiveUS20070041978A1Enhances enzymatic reactionImmunoglobulins against blood coagulation factorsFactor VIIBlood coagulation factor VIIIBlood Coagulation Factor X
The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX / activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII / activated blood coagulation factor VIII which enhances the enzymatic reaction.
Owner:CHUGAI PHARMA CO LTD
Double Specific Antibodies Substituting For Functional Proteins
InactiveUS20080075712A1Reduced activityOutstanding sustainabilityImmunoglobulins against blood coagulation factorsNervous disorderBlood coagulation factor VIIIBlood Coagulation Factor X
The present inventors succeeded in separating bispecific antibodies that functionally substitute for ligands of type I interferon receptors comprising two types of molecules: AR1 chain and AR2 chain. Furthermore, the present inventors succeeded in producing bispecific antibodies that substitute for the enzyme reaction-accelerating function of blood coagulation factor VIII / activated blood coagulation factor VIII, which bind to both blood coagulation factor IX / activated blood coagulation factor IX and blood coagulation factor X.
Owner:CHUGAI PHARMA CO LTD
Protein Microspheres Retaining Pharmacokinetic and Pharmacodynamic Properties
ActiveUS20070207210A1Reduce solubilityImmunoglobulins against blood coagulation factorsPowder deliveryHigh concentrationMicrosphere
The present disclosure relates to compositions of methods of making and compositions small compositions of particles of an active agent. In accordance with the method of production, the active agent is dissolved in an aqueous or aqueous-miscible solvent containing a dissolved phase-separation enhancing agent (PSEA) to form a solution in a single liquid phase. The solution is subjected to a liquid-solid phase separation to cause the active agent to form small spherical particles that are substantially amorphous or non-crystalline and are injectable through fine bore needles at high concentrations. The particles exhibit the pharmacokinetic and pharmacodynamnic properties of the active agent. The disclosure has special application for higher molecular weight proteins such as antibodies.
Owner:BAXTER INT INC +1
Heterodimerized polypeptide
ActiveUS20140199294A1Improve homogeneityImmunoglobulins against blood coagulation factorsHybrid immunoglobulinsChemistryAmino acid
The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved Fc region function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or only the second polypeptide by conventional technology.
Owner:CHUGAI PHARMA CO LTD
Separate-cistron contructs for secretion of aglycosylated antibodies from prokaryotes
InactiveUS6979556B2Immunoglobulins against blood coagulation factorsSugar derivativesBiological studiesProkaryotic expression
The present invention provides methods and compositions for improved expression and production of recombinant antibodies in prokaryotic expression systems. Particularly contemplated are prokaryotic expression and production of full length aglycosylated antibodies. The antibody products of the invention can be used in various aspects of biological research, diagnosis and medical treatment.
Owner:GENENTECH INC
Methods of optimizing antibody variable region binding affinity
InactiveUS6849425B1Immunoglobulins against blood coagulation factorsHybrid immunoglobulinsAntibody variable regionAvidity
The invention provides a method of conferring donor CDR binding affinity onto an antibody acceptor variable region framework. The invention also provides a method of simultaneously grafting and optimizing the binding affinity of a variable region binding fragment. A method of optimizing the binding affinity of an antibody variable region is also provided.
Owner:IXSYS
Compositions and methods for treating coagulation related disorders
InactiveUS20060159675A1Initiate and prolong such disorderRelieve symptomsImmunoglobulins against blood coagulation factorsAntibacterial agentsDiseaseTissue factor
Disclosed are methods for preventing or treating sepsis, a sepsis-related condition or an inflammatory disease in a mammal. In one embodiment, the method includes administering to the mammal a therapeutically effective amount of at least one humanized antibody, chimeric antibody, or fragment thereof that binds specifically to tissue factor (TF) to form a complex in which factor X or factor IX binding to the complex is inhibited and the administration is sufficient to prevent or treat the sepsis in the mammal. The invention has a wide spectrum of useful applications including treating sepsis, disorders related to sepsis, and inflammatory diseases such as arthritis.
Owner:GENENTECH INC
Antibody Substituting for Function of Blood Coagulation Factor VIII
InactiveUS20100003254A1Enhances enzymatic reactionShorten clotting timeImmunoglobulins against blood coagulation factorsAntibody ingredientsBlood coagulation factor VIIIAntiendomysial antibodies
The present inventors produced a variety of bispecific antibodies that specifically bind to both F. IX / F. IXa and F. X, and functionally substitute for F. VIIIa, i.e., have a cofactor function to promote F. X activation via F. IXa. Among these antibodies, the antibody A44 / B26 reduced coagulation time by 50 seconds or more as compared to that observed when the antibody was not added. The present inventors produced a commonly shared L chain antibody from this antibody using L chains of A44, and showed that A44L can be used as commonly shared L chains, although the activity of the resulting antibody is reduced compared to the original antibody (A44HL-B26HL). Further, with appropriate CDR shuffling, the present inventors successfully produced highly active multispecific antibodies that functionally substitute for coagulation factor VIII.
Owner:CHUGAI PHARMA CO LTD
Bispecific antibody substituting for functional proteins
ActiveUS8062635B2Enhances enzymatic reactionImmunoglobulins against blood coagulation factorsFactor VIIBlood coagulation factor VIIIBlood Coagulation Factor X
The present inventors succeeded in constructing bispecific antibodies, which bind to both the blood coagulation factor IX / activated blood coagulation factor IX and blood coagulation factor X, and functionally substitute for blood coagulation factor VIII / activated blood coagulation factor VIII which enhances the enzymatic reaction.
Owner:CHUGAI PHARMA CO LTD
Engineered Immunoglobulin Heavy Chain-Light Chain Pairs And Uses Thereof
ActiveUS20140200331A1Immunoglobulins against blood coagulation factorsAnimal cellsImmunoglobulin heavy chainHeavy chain
The present invention provides heterodimer pairs comprising a first heterodimer and a second heterodimer wherein each heterodimer comprises an immunoglobulin heavy chain or fragment thereof and an immunoglobulin light chain. At least one of the heterodimers comprises amino acid modifications in the CH1 and / or CL domains, amino acid modifications in the VH and / or VL domains or a combination thereof. The modified amino acid residues are part of the interface between the light chain and heavy chain and are modified in order to create preferential pairing between each heavy chain and a desired light chain such that when the two heavy chains and two light chains of the heterodimer pair are co-expressed in a mammalian cell, the heavy chain of the first heterodimer preferentially pairs with one of the light chains rather than the other. Likewise, the heavy chain of the second heterodimer preferentially pairs with the second light chain rather than first.
Owner:ZYMEWORKS INC
Composition exhibiting a von Willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
InactiveUS20050266528A1Immunoglobulins against blood coagulation factorsFactor VIIFactor VIII vWFProteinase activity
Owner:BAXALTA INC
Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
InactiveUS20070077249A1Pass efficientlyImmunoglobulins against blood coagulation factorsAntibacterial agentsSingle-domain antibodyGreek letter alpha
The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.
Owner:ABLYNX NV
Anti-C5 alpha antibodies
InactiveUS7999081B2Immunoglobulins against blood coagulation factorsNervous disorderDiseaseNucleotide
The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.
Owner:ADIENNE SA
Polypeptide modification method for purifying polypeptide multimers
InactiveUS20130018174A1Efficient purificationProduce efficientlyImmunoglobulins against blood coagulation factorsFungiBlood plasmaSpecific antibody
The present invention provides efficient methods based on alteration of the protein A-binding ability, for producing or purifying multispecific antibodies having the activity of binding to two or more types of antigens to high purity through a protein A-based purification step alone. The methods of the present invention for producing or purifying multispecific antibodies which feature altering amino acid residues of antibody heavy chain constant region and / or variable region. Multispecific antibodies with an altered protein A-binding ability, which exhibit plasma retention comparable or longer than that of human IgG1, can be efficiently prepared in high purity by introducing amino acid alterations of the present invention into antibodies.
Owner:CHUGAI PHARMA CO LTD
Factor IX/factor IXa activating antibodies and antibody derivatives
InactiveUS7033590B1High activityRapid blood coagulationImmunoglobulins against blood coagulation factorsImmunoglobulins against blood group antigensActivated factor IXFactor ii
Owner:BAXALTA INC
Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes
InactiveUS20050123997A1Low immunogenicityImmunoglobulins against blood coagulation factorsFactor VIIEpitopeVaccine Immunogenicity
Specific amino acid loci of human fVIII interact with inhibitory antibodies of hemophilia patients after being treated with fVIII. Modified fVIII is disclosed in which the amino acid sequence is changed by multiple substitutions in human fVIII A2 and C2 domains. The modified fVIII is useful for hemophiliacs, either to avoid or prevent the action of inhibitory antibodies.
Owner:EMORY UNIVERSITY
Serum albumin binding peptides for tumor targeting
InactiveUS20060228364A1Altered pharmacodynamicsFacilitated DiffusionImmunoglobulins against blood coagulation factorsPeptide-nucleic acidsAbnormal tissue growthTumor targeting
Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.
Owner:GENENTECH INC
Parenteral pharmaceutical composition containing humanized monoclonal antibody fragment and stabilizing method thereof
InactiveUS20050118167A1Immunoglobulins against blood coagulation factorsPharmaceutical delivery mechanismAntibody fragmentsMedicine
This invention relates to a parenteral pharmaceutical composition which comprises a humanized monoclonal antibody fragment, a nonionic surface active agent and saccharides, wherein its pH is weakly acidic. The invention also relates to a method for the stabilization of a humanized antibody fragment, which comprises formulating a nonionic surface active agent and saccharides and adjusting the pH to a weakly acidic level. According to the invention, a stable parenteral pharmaceutical composition or parenteral pharmaceutical preparation can be provided, which comprises a humanized monoclonal antibody fragment and has no using limitations such as cold place preservation avoiding freezing, transfer and handling avoiding shaking, particle removing operation by a filter when used and the like.
Owner:ASTELLAS PHARMA INC
Hemagglutinin polypeptides, and reagents and methods relating thereto
InactiveUS20080241918A1Immunoglobulins against blood coagulation factorsPeptide/protein ingredientsHemagglutininGlycan
The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.
Owner:MASSACHUSETTS INST OF TECH
Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
InactiveUS6926894B2Immunoglobulins against blood coagulation factorsFactor VIIFactor VIII vWFProteinase activity
The invention relates to vWF cleaving entities having a molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an N-terminal amino acid sequence of AAGGILHLELLV (SEQ ID NO: 1), vWF cleaving complexes and methods for their production.
Owner:BAXALTA INC
Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
ActiveUS20130330345A1High activityLow F.Xase inhibitory actionImmunoglobulins against blood coagulation factorsAnimal cellsBlood coagulation factor VIIIAntigen
Various bispecific antibodies that specifically bind to both blood coagulation factor IX / activated blood coagulation factor IX and blood coagulation factor X and functionally substitute for the cofactor function of blood coagulation factor VIII, that is, the function to promote activation of blood coagulation factor X by activated blood coagulation factor IX, were produced. From these antibodies, multispecific antigen-binding molecules having a high activity of functionally substituting for blood coagulation factor VIII were successfully discovered.
Owner:CHUGAI PHARMA CO LTD
Inert format
ActiveUS20150337049A1Immunoglobulins against blood coagulation factorsAntibacterial agentsAmino acid substitutionAmino acid
Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.
Owner:GENMAB AS
Antibodies Comprising an Ion Concentration Dependent Antigen-Binding Domain, Fc Region Variants, IL-8-Binding Antibodies, and Uses Thereof
ActiveUS20160229908A1Improved pharmacokinetic propertiesImprove clearanceImmunoglobulins against blood coagulation factorsAntibacterial agentsAntiendomysial antibodiesPharmaceutical drug
One nonexclusive aspect provides molecules further improved from antibodies that can bind to antigens in an ion concentration-dependent manner. An alternative nonexclusive aspect provides safe and more advantageous Fc region variants that have decreased binding to pre-existing ADA. An alternative nonexclusive aspect provides novel IL-8 antibodies that are superior as pharmaceuticals.
Owner:CHUGAI PHARMA CO LTD
Methods and compositions for the treatment of meconium aspiration syndrome
InactiveUS20070065433A1Reduce morbidityReduce mortalityImmunoglobulins against blood coagulation factorsPeptide/protein ingredientsAntiendomysial antibodiesComplement S-Protein
A method for preventing or treating meconium aspiration syndrome (“MAS”) by administering a meconium aspiration syndrome preventing or treating amount of one or more complement inhibitors to a patient likely to develop or suffering from MAS. The complement inhibitors are preferably antibodies that bind to and inhibit complement proteins involved in the formation of the membrane attach complex, preferably anti-Factor D or anti-C5 antibodies. The complement inhibitors can be used alone or in combination with other MAS therapies to decrease the morbidity and mortality caused by MAS.
Owner:MOLLNES TOM EIRIK +1
Method of stabilizing protein
InactiveUS20050171339A1Increase valueImprove and qualityImmunoglobulins against blood coagulation factorsImmunoglobulin superfamilyGlycineAsparagine
The present inventors revealed that deamidation of an antibody can be suppressed without influencing its activity by substituting a glycine that is located adjacent to an asparagine with another amino acid.
Owner:CHUGAI PHARMA CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com